ASCO 2023 | Clinical implications of neoadjuvant immunotherapy in CSCC

Charlotte Zuur, Leiden University Medical Center, Leiden, The Netherlands, discusses the clinical implications of the MATISSE trial (NCT02760498) for patients with cutaneous squamous cell carcinoma (CSCC). The trial results principally evaluated whether patients with a deep response to neoadjuvant immunotherapy might be spared intensive standard-of-care surgery and radiotherapy. This interview took place during the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.